220 related articles for article (PubMed ID: 14689584)
21. Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer.
Reddy GP; Barrack ER; Dou QP; Menon M; Pelley R; Sarkar FH; Sheng S
J Cell Biochem; 2006 Aug; 98(6):1408-23. PubMed ID: 16619263
[TBL] [Abstract][Full Text] [Related]
22. Hepatocyte growth factor-activated NF-kappaB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines.
Tacchini L; De Ponti C; Matteucci E; Follis R; Desiderio MA
Carcinogenesis; 2004 Nov; 25(11):2089-100. PubMed ID: 15240510
[TBL] [Abstract][Full Text] [Related]
23. Effects of IKK inhibitor PS1145 on NF-kappaB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells.
Yemelyanov A; Gasparian A; Lindholm P; Dang L; Pierce JW; Kisseljov F; Karseladze A; Budunova I
Oncogene; 2006 Jan; 25(3):387-98. PubMed ID: 16170348
[TBL] [Abstract][Full Text] [Related]
24. NF-kappaB in solid tumors.
Pacifico F; Leonardi A
Biochem Pharmacol; 2006 Oct; 72(9):1142-52. PubMed ID: 16956585
[TBL] [Abstract][Full Text] [Related]
25. Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma.
Loercher A; Lee TL; Ricker JL; Howard A; Geoghegen J; Chen Z; Sunwoo JB; Sitcheran R; Chuang EY; Mitchell JB; Baldwin AS; Van Waes C
Cancer Res; 2004 Sep; 64(18):6511-23. PubMed ID: 15374962
[TBL] [Abstract][Full Text] [Related]
26. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical analysis of NF-kappaB signaling proteins IKKepsilon, p50/p105, p52/p100 and RelA in prostate cancers.
Seo SI; Song SY; Kang MR; Kim MS; Oh JE; Kim YR; Lee JY; Yoo NJ; Lee SH
APMIS; 2009 Aug; 117(8):623-8. PubMed ID: 19664134
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of NF-kappaB1 and NF-kappaB2 activation in prostate cancer cells treated with antibody against the carboxyl terminal domain of GRP78: effect of p53 upregulation.
Misra UK; Kaczowka S; Pizzo SV
Biochem Biophys Res Commun; 2010 Feb; 392(4):538-42. PubMed ID: 20097177
[TBL] [Abstract][Full Text] [Related]
29. Requirement of RhoA activity for increased nuclear factor kappaB activity and PC-3 human prostate cancer cell invasion.
Hodge JC; Bub J; Kaul S; Kajdacsy-Balla A; Lindholm PF
Cancer Res; 2003 Mar; 63(6):1359-64. PubMed ID: 12649199
[TBL] [Abstract][Full Text] [Related]
30. Androgen-mediated resistance to apoptosis.
Coffey RN; Watson RW; O'Neill AJ; Mc Eleny K; Fitzpatrick JM
Prostate; 2002 Dec; 53(4):300-9. PubMed ID: 12430141
[TBL] [Abstract][Full Text] [Related]
31. Guanosine phosphate binding protein coupled receptors in prostate cancer: a review.
Raj GV; Barki-Harrington L; Kue PF; Daaka Y
J Urol; 2002 Mar; 167(3):1458-63. PubMed ID: 11832770
[TBL] [Abstract][Full Text] [Related]
32. Androgen receptor is up-regulated by a BLT2-linked pathway to contribute to prostate cancer progression.
Lee JW; Kim GY; Kim JH
Biochem Biophys Res Commun; 2012 Apr; 420(2):428-33. PubMed ID: 22426480
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activity of NF-kB decoy oligodeoxynucleotides in a prostate cancer cell line.
Fang Y; Sun H; Zhai J; Zhang Y; Yi S; Hao G; Wang T
Asian Pac J Cancer Prev; 2011; 12(10):2721-6. PubMed ID: 22320981
[TBL] [Abstract][Full Text] [Related]
34. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen.
Palayoor ST; Youmell MY; Calderwood SK; Coleman CN; Price BD
Oncogene; 1999 Dec; 18(51):7389-94. PubMed ID: 10602496
[TBL] [Abstract][Full Text] [Related]
35. Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration.
Liu JW; Shen JJ; Tanzillo-Swarts A; Bhatia B; Maldonado CM; Person MD; Lau SS; Tang DG
Oncogene; 2003 Mar; 22(10):1475-85. PubMed ID: 12629510
[TBL] [Abstract][Full Text] [Related]
36. Growth factors and oncogenes in prostate cancer.
Thompson TC
Cancer Cells; 1990 Nov; 2(11):345-54. PubMed ID: 2282250
[TBL] [Abstract][Full Text] [Related]
37. Roles of p53, NF-κB and the androgen receptor in controlling NGAL expression in prostate cancer cell lines.
Chappell WH; Candido S; Abrams SL; Russo S; Ove R; Martelli AM; Cocco L; Ramazzotti G; Cervello M; Montalto G; Steelman LS; Leng X; Arlinghaus RB; Libra M; McCubrey JA
Adv Biol Regul; 2018 Aug; 69():43-62. PubMed ID: 29861174
[TBL] [Abstract][Full Text] [Related]
38. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays.
Bubendorf L; Kononen J; Koivisto P; Schraml P; Moch H; Gasser TC; Willi N; Mihatsch MJ; Sauter G; Kallioniemi OP
Cancer Res; 1999 Feb; 59(4):803-6. PubMed ID: 10029066
[TBL] [Abstract][Full Text] [Related]
39. ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-κB and drives prostate cancer progression.
Longoni N; Sarti M; Albino D; Civenni G; Malek A; Ortelli E; Pinton S; Mello-Grand M; Ostano P; D'Ambrosio G; Sessa F; Garcia-Escudero R; Thalmann GN; Chiorino G; Catapano CV; Carbone GM
Cancer Res; 2013 Jul; 73(14):4533-47. PubMed ID: 23687337
[TBL] [Abstract][Full Text] [Related]
40. Nuclear factor κB predicts poor outcome in patients with hormone-naive prostate cancer with high nuclear androgen receptor.
MacKenzie L; McCall P; Hatziieremia S; Catlow J; Adams C; McArdle P; Seywright M; Tanahill C; Paul A; Underwood M; Mackay S; Plevin R; Edwards J
Hum Pathol; 2012 Sep; 43(9):1491-500. PubMed ID: 22406367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
